


AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A compound of formula I:



wherein

X¹, X², X³, X⁴, and X⁵ are independently selected from the group consisting of C, CR⁵, N, O, and S, wherein at least one of X¹, X², X³, X⁴, and X⁵ is not N;

X⁶ is selected from the group consisting of a bond and CR⁵R⁶;

X⁷ is CR⁵ or N;

X⁸ is selected from the group consisting of a bond, CR⁵R⁶, NR⁵, O, S, SO, and SO₂;

X⁹ is CR⁵-or-N;

X¹⁰ is selected from the group consisting of a bond, OR⁵R⁶, (CR⁵R⁶)₂, O, S, and NR⁵;

R¹ is selected from the group consisting of hydroxy, halo, nitro, C₁₋₆alkylhalo, OC₁₋₆alkylhalo, C₁₋₆alkyl, OC₁₋₆alkyl, C₂₋₆alkenyl, OC₂₋₆alkenyl, C₂₋₆alkynyl, OC₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, OC₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, OC₀₋₆alkylaryl, CHO, (CO)R⁵, O(CO)R⁵, O(CO)OR⁵, O(CN)OR⁵, C₁₋₆alkylOR⁵, OC₂₋₆alkylOR⁵, C₁₋₆alkyl(CO)R⁵, OC₁₋₆alkyl(CO)R⁵, C₀₋₆alkylCO₂R⁵, OC₁₋₆alkylCO₂R⁵, C₀₋₆alkylcyano, OC₂₋₆alkylcyano, C₀₋₆alkylNR⁵R⁶, OC₂₋₆alkylNR⁵R⁶, C₁₋₆alkyl(CO)NR⁵R⁶, OC₁₋₆alkyl(CO)NR⁵R⁶, C₀₋₆alkylNR⁵(CO)R⁶, OC₂₋₆alkylNR⁵(CO)R⁶, C₀₋₆alkylNR⁵(CO)NR⁵R⁶, C₀₋₆alkylSR⁵, OC₂₋₆alkylSR⁵, C₀₋₆alkyl(SO)R⁵, OC₂₋₆alkyl(SO)R⁵, C₀₋₆alkylSO₂R⁵, OC₂₋₆alkylSO₂R⁵, C₀₋₆alkyl(SO₂)NR⁵R⁶, OC₂₋₆alkyl(SO₂)NR⁵R⁶, C₀₋₆alkylNR⁵(SO₂)R⁶, OC₂₋₆alkylNR⁵(SO₂)R⁶, (CO)NR⁵R⁶, O(CO)NR⁵R⁶, NR⁵OR⁶, C₀₋₆alkylNR⁵(CO)OR⁶, OC₂₋₆alkylNR⁵(CO)OR⁶, SO₃R⁵ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R² is selected from the group consisting of hydrogen, hydroxy, halo, nitro, C₁₋₆alkylhalo, OC₁₋₆alkylhalo, C₁₋₆alkyl, OC₁₋₆alkyl, C₂₋₆alkenyl, OC₂₋₆alkenyl, C₂₋₆alkynyl, OC₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, OC₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, OC₀₋₆alkylaryl, CHO, (CO)R⁵, O(CO)R⁵,

| O(CO)OR⁵, O(CN)OR⁵, C₁₋₆alkylOR⁵, OC₂₋₆alkylOR⁵, C₁₋₆alkyl(CO)R⁵, OC₁₋₆alkyl(CO)R⁵, C₀₋₆alkylCO₂R⁵, OC₁₋₆alkylCO₂R⁵, C₀₋₆alkylcyano, OC₂₋₆alkylcyano, C₀₋₆alkylNR⁵R⁶, OC₂₋₆alkylNR⁵R⁶, C₁₋₆alkyl(CO)NR⁵R⁶, OC₁₋₆alkyl(CO)NR⁵R⁶, C₀₋₆alkylNR⁵(CO)R⁶, OC₂₋₆alkylNR⁵(CO)R⁶, C₀₋₆alkylNR⁵(CO)NR⁵R⁶, C₀₋₆alkylSR⁵, OC₂₋₆alkylSR⁵, C₀₋₆alkyl(SO)R⁵, OC₂₋₆alkyl(SO)R⁵, C₀₋₆alkylSO₂R⁵, OC₂₋₆alkylSO₂R⁵, C₀₋₆alkyl(SO₂)NR⁵R⁶, OC₂₋₆alkyl(SO₂)NR⁵R⁶, C₀₋₆alkylNR⁵(SO₂)R⁶, OC₂₋₆alkylNR⁵(SO₂)R⁶, C₀₋₆alkylNR⁵(SO₂)R⁶, (CO)NR⁵R⁶, O(CO)NR⁵R⁶, NR⁵OR⁶, C₀₋₆alkylNR⁵(CO)OR⁶, OC₂₋₆alkylNR⁵(CO)OR⁶, SO₃R⁵ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R³ is a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R⁴ is selected from the group consisting of hydroxy, halo, nitro, C₁₋₆alkylhalo, OC₁₋₆alkylhalo, C₁₋₆alkyl, OC₁₋₆alkyl, C₂₋₆alkenyl, OC₂₋₆alkenyl, C₂₋₆alkynyl, OC₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, OC₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, OC₀₋₆alkylaryl, CHO, (CO)R⁵, O(CO)R⁵, O(CO)OR⁵, O(CN)OR⁵, C₁₋₆alkylOR⁵, OC₂₋₆alkylOR⁵, C₁₋₆alkyl(CO)R⁵, OC₁₋₆alkyl(CO)R⁵, C₀₋₆alkylCO₂R⁵, OC₁₋₆alkylCO₂R⁵, C₀₋₆alkylcyano, OC₂₋₆alkylcyano, C₀₋₆alkylNR⁵R⁶, OC₂₋₆alkylNR⁵R⁶, C₁₋₆alkyl(CO)NR⁵R⁶, OC₁₋₆alkyl(CO)NR⁵R⁶, C₀₋₆alkylNR⁵(CO)R⁶, OC₂₋₆alkylNR⁵(CO)R⁶, C₀₋₆alkylNR⁵(CO)NR⁵R⁶, C₀₋₆alkylSR⁵, OC₂₋₆alkylSR⁵, C₀₋₆alkyl(SO)R⁵, OC₂₋₆alkyl(SO)R⁵, C₀₋₆alkylSO₂R⁵, OC₂₋₆alkylSO₂R⁵, C₀₋₆alkyl(SO₂)NR⁵R⁶, OC₂₋₆alkyl(SO₂)NR⁵R⁶, C₀₋₆alkylNR⁵(SO₂)R⁶, OC₂₋₆alkylNR⁵(SO₂)R⁶, C₀₋₆alkylNR⁵(SO₂)R⁶, (CO)NR⁵R⁶, O(CO)NR⁵R⁶, NR⁵OR⁶, C₀₋₆alkylNR⁵(CO)OR⁶, OC₂₋₆alkylNR⁵(CO)OR⁶, SO₃R⁵ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

$\text{C}_6\text{alkylSO}_2\text{R}^5$, $\text{OC}_{2-6}\text{alkylSO}_2\text{R}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $(\text{CO})\text{NR}^5\text{R}^6$, $\text{O}(\text{CO})\text{NR}^5\text{R}^6$, NR^5OR^6 , $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R^5 and R^6 are independently selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_3\text{-cycloalkyl}$ and aryl;

A is selected from the group consisting of hydrogen, hydroxy, halo, nitro, $\text{C}_{1-6}\text{alkylhalo}$, $\text{OC}_{1-6}\text{alkylhalo}$, $\text{C}_{1-6}\text{alkyl}$, $\text{OC}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{OC}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{OC}_{2-6}\text{alkynyl}$, $\text{C}_{0-6}\text{alkylC}_3\text{-cycloalkyl}$, $\text{OC}_{0-6}\text{alkylC}_3\text{-cycloalkyl}$, $\text{C}_{0-6}\text{alkylaryl}$, $\text{OC}_{0-6}\text{alkylaryl}$, CHO , $(\text{CO})\text{R}^5$, $\text{O}(\text{CO})\text{R}^5$, $\text{O}(\text{CO})\text{OR}^5$, $\Theta(\text{CN})\Theta\text{R}^5$, $\text{C}_{1-6}\text{alkylOR}^5$, $\text{OC}_{2-6}\text{alkylOR}^5$, $\text{C}_{1-6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{OC}_{1-6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{C}_{0-6}\text{alkylCO}_2\text{R}^5$, $\text{OC}_{1-6}\text{alkylCO}_2\text{R}^5$, $\text{C}_{0-6}\text{alkylcyano}$, $\text{OC}_{2-6}\text{alkylcyano}$, $\text{C}_{0-6}\text{alkylNR}^5\text{R}^5$, $\Theta\text{C}_{2-6}\text{alkylNR}^5\text{R}^8$, $\text{C}_{4-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^8$, $\Theta\text{C}_{4-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^8$, $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{R}^8$, $\Theta\text{C}_{2-6}\text{alkylNR}^5(\text{CO})\text{R}^8$, $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{NR}^5\text{R}^8$, $\text{C}_{0-6}\text{alkylSR}^5$, $\text{OC}_{2-6}\text{alkylSR}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{OC}_{2-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{C}_{0-6}\text{alkylSO}_2\text{R}^5$, $\text{OC}_{2-6}\text{alkylSO}_2\text{R}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^8$, $\Theta\text{C}_{2-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^8$, $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^8$, $\Theta\text{C}_{2-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^8$, $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^8$, $(\text{CO})\text{NR}^5\text{R}^8$, $\Theta(\text{CO})\text{NR}^5\text{R}^8$, NR^5OR^8 , $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{OR}^8$, $\Theta\text{C}_{2-6}\text{alkylNR}^5(\text{CO})\text{OR}^8$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

membered ring containing atoms independently selected from the group consisting of C, N, O and S;

n is 0, 1, 2, 3, or 4; or

a pharmaceutically acceptable salt or hydrate thereof;

provided that:

a) when $\underline{X}_2\text{-}\underline{X}^2 = \underline{X}_4\text{-}\underline{X}^4 = \underline{X}_5\text{-}\underline{X}^5 = \text{N}$, and either of $\underline{X}_8\text{-}\underline{X}^8$ or $\underline{X}_{10}\text{-}\underline{X}^{10}$ is a bond, then $\underline{X}_9\text{-}\underline{X}^9$ is not N,

b) when X^7 is N at least two of X^1 , X^2 , X^3 , X^4 , and X^5 are not N,

c) X^1 and X^3 are not O;

and provided that the compound is not:

8-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine,

8-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-thiophen-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine,

8-[5-(5-Chloro-2-fluoro-phenyl)-1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine;

8-[5-(3-Chloro-phenyl)-1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[5-(5-Chloro-2-fluoro-phenyl)-1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[5-(3-Chloro-phenyl)-1,3,4]oxadiazol-2-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[1-[5-(3-Chloro-phenyl)-1,3,4]oxadiazol-2-yl]-ethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[5-(5-Chloro-2-fluoro-phenyl)-1,2,4]oxadiazol-3-ylmethyl]-3-furan-2-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[1-[5-(3-Chloro-phenyl)-1,2,4]oxadiazol-3-yl]-ethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

3-Pyridin-4-yl-8-[1-(5-m-tolyl)-1,2,4]oxadiazol-3-yl]-ethyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

(+)-8-{(1S)-1-[5-(3-chlorophenyl)-1,2,4]oxadiazol-3-yl}-ethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

(-)-8-{(1R)-1-[5-(3-chlorophenyl)-1,2,4]oxadiazol-3-yl}-ethyl]-3-pyridin-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

~~3-[5-(3-Pyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]-[1,3,4]oxadiazol-2-yl]benzonitrile,~~

~~3-[5-[3-(2-Methoxypyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]-[1,3,4]oxadiazol-2-yl]benzonitrile,~~

~~3-[5-[3-(2-Methoxypyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]-[1,2,4]oxadiazol-3-yl]benzonitrile,~~

~~3-[3-[3-(3-pyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl)methyl]-1,2,4-oxadiazol-5-yl]benzonitrile,~~

~~3-(3-[3-(2-methoxypyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl)methyl]-1,2,4-oxadiazol-5-yl)benzonitrile,~~

~~3-[5-[3-(3-pyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl)methyl]-1,2,4-oxadiazol-3-yl]benzonitrile, and~~

~~3-[5-[3-(2-Hydroxypyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]-[1,2,4]oxadiazol-3-yl]benzonitrile.~~


2. (Withdrawn) The compound according to claim 1, provided that the compound is not 8-[5-(5-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-furan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine,

3. **(Original)** The compound according to claim 1, wherein R¹ is halo, C₁₋₆alkylhalo, C₁₋₆alkyl, OC₁₋₆alkyl, or C₀₋₆alkylcyano.

4. **(Original)** The compound according to claim 1, wherein R² is hydrogen or halo.


5. **(Original)** The compound according to claim 1, wherein R² is fluorine.

6. **(Original)** The compound according to claim 1, of Formula II:



7. **(Original)** The compound according to claim 6, wherein X⁷ is N.


8. **(Currently Amended)** The compound according to claim ~~0~~claim 1, of Formula III:




9. **(Original)** The compound according to claim 8, wherein X³ is C.

10. **(Original)** The compound according to claim 8, wherein X³ is N.

11. **(Currently Amended)** The compound according to claim ~~0~~claim 1, wherein the ring containing X¹, X², X³, X⁴, and X⁵ is selected from the group consisting of:



12. **(Original)** The compound according to claim 11, wherein the ring is selected from the group consisting of:



13. **(Original)** The compound according to claim 11, wherein X^7 is N.

14. **(Withdrawn)** The compound according to claim 13, wherein X^8 is a bond.

15. **(Original)** The compound according to claim 13, wherein X^8 is S.

16. **(Withdrawn)** The compound according to claim 14, wherein X^9 is CR^5 .

17. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is NR^5 .

18. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is O.

19. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is CR^5R^6 .

20. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is $(CR^5R^6)_2$.


21. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is a bond.

22. **(Original)** The compound according to claim 15, wherein X^9 is CR^5 .

23. **(Original)** The compound according to claim 22, wherein X^{10} is a bond.

24. **(Withdrawn)** The compound according to claim 14, wherein X^9 is N.

25. **(Currently Amended)** The compound according to claim 11, wherein the fused ring containing X^7 , X^8 , X^9 , and X^{10} is selected from the group consisting of:



26. **(Currently Amended)** The compound according to claim 1 selected from the group consisting of which is

7-[5-(5-Chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-3-(2-thienyl)-6,7-dihydro-5H-[1,2,4]triazolo[3,4-b][1,3]thiazine,

9-{[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

9-{1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl}-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

7-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-3-pyridin-4-yl-6,7-dihydro-5H-pyrrole[2,1-e][1,2,4]triazole,

9-{[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-3-(trifluoromethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

8-[3-(3-Chlorophenyl)-[1,2,4]oxadiazol-5-yl]-3-(4-methoxyphenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine,

8-[3-(3-Chlorophenyl)-[1,2,4]oxadiazol-5-yl]-3-(4-methoxyphenyl)-7-m

ethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine,

9-{[5-(3-chlorophenyl)isoxazol-3-yl]methyl}-3-(3,5-difluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

9-{{5-(3-chlorophenyl)isoxazol-3-yl}methyl}-3-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine;

9-{{5-(3-chlorophenyl)isoxazol-3-yl}methyl}-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine;

9-{{5-(5-chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl}methyl}-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine;

9-{{5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl}methyl}-3-(3,5-difluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine;

9-{{5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl}methyl}-3-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine, and

pharmaceutically acceptable salts thereof.

27. **(Currently Amended)** A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1, 3-13, 15, 22, 23, 25 and 26, and one or more pharmaceutically acceptable diluents, excipients, and/or inert carriers.

28. **(Canceled)**

29. **(Canceled)**

30. **(Canceled)**

31. **(Canceled)**

32. **(Canceled)**

33. **(Currently Amended)** The method according to any one of claims 3235, 36 and 37, wherein the mammal is a human.

34. **(Canceled)**

35. **(Currently Amended)** ~~The A method for the treatment of according to claim 32, wherein the disorder is a psychiatric disorder comprising administering to a mammal in need thereof a therapeutically effective amount of the compound according to claim 1.~~

36. **(Currently Amended)** ~~The A method for the treatment of according to claim 32, wherein the disorders are selected from chronic and acute pain disorders comprising~~

administering to a mammal in need thereof a therapeutically effective amount of the compound according to claim 1.

37. **(Currently Amended)** The A method for the treatment of gastro-esophageal reflux disorder (GERD) comprising administering to a mammal in need thereof a therapeutically effective amount of the compound according to claim 1 according to claim 32, wherein the disorder is a gastrointestinal disorder.

38. **(Canceled)**